Abhishek S.’s Post

"Today’s drug discovery favors precision drug therapy, push­ing complex modalities like combination therapies and biologics, along with cell- and gene-based therapeutics to the forefront. Major advances in areas, such as synthetic biology, advanced dis­ease model creation, and integrated multi-omics-based work­flows, continue to evolve our understanding of human pathophysiologies and bring the hope of new treatments to the market with an ever-increasing speed. Aside from being intricate, they are also lengthy processes with greater risks for human error." John Fuller, Commercial Product Manager, discusses with Drug Development & Delivery solutions to alleviate bottlenecks and streamline workflows in drug discovery through acoustic liquid handling: https://lnkd.in/epVC_e6A #LiquidHandling #DrugDiscovery #BECLSnews #InTheNews

Using DNA nanoswitch technology, the Wyss' Lab-on-a-Molecule project has created a platform that enables high-throughput, low-cost screening of libraries composed of small molecules, biologics, peptides, and other types of compounds to discover novel drug candidates based on how they affect the function of disease-relevant proteins. #DrugDevelopment #DNA #Nanotechnology https://lnkd.in/ev5dK-w3

Algorae Pharmaceuticals Ltd (#ASX Code: #1AI) #ASXnews - Positive results from AI-116 in vitro studies. • Pre-clinical data demonstrates neuroprotective effect of AI-116, exceeding that for the existing FDA registered drug for dementia, Donepezil (originally marketed as Aricept). • Cell viability increased by 20.1% for AI-116 versus 2.1% for Donepezil, in pre-clinical studies. • Results demonstrate synergistic method of action within AI-116. • RNA sequencing analysis to commence to further assess AI-116, including for neuroinflammation which plays a multifaceted role in the pathogenesis of dementia.  #ai #artificialintelligence #biotech #pharmaceutical

🔬🧬 The Future of Biologics Research! 🧬🔬 Join us on 18 November 2024 from 13:30 - 14:00 at the Antibody Therapeutics Xchange - Brussels for an exclusive Spotlight Presentation on "Innovative Solutions Set New Standards in Quality & Speed for Biologics Research." 🚀 In today’s fast-paced biologics development, having flexible, end-to-end solutions is essential to drive efficiency. This session will dive into our integrated modular services—from antibody discovery 🧪 and protein engineering 🧫 to production ⚙️ and in vitro & in vivo testing🔬—that streamline the research process. 🌟 Key topics include: 🟡 Tailored services for each stage of antibody drug development 🧬 🟡 Advanced high-titer expression platform enabling high yields in less time 🧪 🟡Innovative bispecific antibody production strategies for >98% heterodimer purity across diverse formats ⚗️ 🧪 Jiansheng Wu, Head of CRO Services, Vice President at WuXi Biologics will share his deep insights and extensive experience, accumulated through over 50 drug development projects and 15 years at Genentech. Register now for FREE to stay ahead in biologics research innovation: https://lnkd.in/e5Vrkbdj Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #BiologicsResearch #AntibodyTherapeutics #ProteinSciences #BiologicsDevelopment #AntibodyEngineering #WuXiBiologics #DrugDevelopment #AntibodyDiscovery #InnovativeSolutions #CMC #ProteinProduction #Biopharma #Biotech #LifeSciences #TherapeuticDiscovery #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

Just in! ☄ This is a recent comprehensive review with captivating visuals about LNP drug delivery. The article talks about how the development of lipid nanoparticles can be a challenging task due to the complex nature of biologics. However, the researchers found that by combining various lipid components, they were able to create lipid nanoparticles that can effectively deliver biologics to the targeted sites in the body. 🎯 Snippet Highlights: 🌍 The article discusses the various techniques used in developing lipid nanoparticles for biologics delivery. It also sheds light on the challenges faced during the process and how they can be overcome. 🌎 The authors found that the composition of the lipid nanoparticles plays a crucial role in determining their efficacy. They also discovered that the size, shape, and surface charge of the nanoparticles can impact their ability to deliver biologics to the target site. 🌏 LNPs have been effective in delivering oligonucleotides, with Pieter Cullis's research group reporting the use of LNPs for delivering SiRNA, resulting in the product #Onpattro® approved by the US #FDA in August 2018. 🌍 The review provides insights into the methods of LNP formulation, including high-energy, low-energy, and organic solvent-based methods, along with comparisons of their advantages and disadvantages. 🌎 The article emphasizes the potential opportunities and current challenges in LNP technology for biologics delivery, offering a comprehensive perspective on this innovative approach. What analytical techniques do you think hold the key to unlocking the full potential of lipid nanoparticles in biopharmaceuticals? ------ Do you like our Snippet Phriday sessions? Recommend, ♻️Repost, if you find it useful. TechnoPharmaSphere LLC. Biopharm Consultant and CRO https://lnkd.in/d_q6PUF https://lnkd.in/gy2zmS5m ⏩P.S. Stay tuned for the detailed insights about Lipid nanoparticles and related content! #Biopharmaceuticals #DrugDelivery #Nanotechnology #Biologics #Innovation #SnippetPhriday

E. coli has long been a workhorse in the biopharmaceutical industry due to its well-characterized nature and ease of use. While it offers advantages like rapid development timelines and lower production costs compared to other cell types, it also has limitations, particularly for certain molecule types and batch-to-batch consistency. But recent advancements in genetic engineering and analytical techniques have significantly enhanced E. coli's potential for protein expression. These improvements have led to the development of new platform processes that optimize biopharmaceutical production for a wider range of protein-based therapeutics. https://lnkd.in/gJMxMRd6

🔬🚀 Don't Miss the Battle of Biologics Modalities! 🧬🧪 We are excited to extend an invitation to the highly anticipated roundtable discussion, "The Battle of Biologics Modalities," scheduled for September 23, 2024, from 16:05-17:05 during the Emerging Technologies Track at the Antibody Therapeutics Xchange - San Francisco 2024. SECURE YOUR COMPLIMENTARY PASS TODAY https://lnkd.in/e4bWB39F 🧫 Key Discussion Topics Include: 🟡 Single Domain Antibodies vs scFvs 🔄 – Delving into the advantages and limitations in discovery platforms, reformatting, and physicochemical properties. 🟡 Common Light Chain Discovery 🧠 – Analyzing the key risk factors for a successful campaign. 🟡 T-cell Engagers vs CARs, ADCs vs Radiolabeled Antibodies ⚔️ – Who will emerge victorious? Let’s explore this dynamic debate. 🎤 Industry Expert: Jane Seagal Jane Seagal, Vice President of Antibody Discovery at Ablexis, LLC and AlivaMab Biologics will lead this insightful discussion. With over a decade of experience in antibody drug discovery, Jane's expertise in in vivo approaches and her innovative work at AbbVie make her the perfect guide through these critical topics. Ensure you don’t miss this unique opportunity to gain insights from a leader in the field and engage in a lively discussion with fellow professionals. 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 🧬 Let’s shape the future of biologics together! #Biologics #AntibodyTherapeutics #EmergingTechnologies #Biotech #SanFrancisco2024 #HealthcareInnovation #Biopharma #LifeSciences #AntibodyEngineering #DrugDiscovery #Immunotherapy #Biotechnology #PharmaInnovation #MedicalResearch #TherapeuticDevelopment #ClinicalResearch #HealthTech #PrecisionMedicine #BiotechIndustry #InnovationInMedicine #NextGenTherapeutics #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

Thoughts on this? >> Australian RNA manufacturer launches; Forge Biologics’ CEO steps down >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #pharma #productmarketing

We are delighted to introduce Dr. Jeff Lin, PhD, a passionate and innovative bioanalytical scientist from Genentech, who will be presenting at the Applied Pharmaceutical Analysis (APA) 2024 Conference. Dr. Lin's talk, titled "Characterizing In Vivo Stability of Large Molecule Conjugates Using Complementary Bioanalytical Tools," is set to be a highlight of the event. As a Senior Scientist in the large molecule bioanalytical group at Genentech, Dr. Lin plays a critical role in supporting preclinical pharmacology analysis. His expertise spans various analytical techniques such as mass spectrometry, capillary electrophoresis, and plate-based immunoassays. With a current focus on oligonucleotide-based modalities, Dr. Lin’s experience also includes antibodies/bispecifics, enzyme replacement therapies, and Fab conjugates. His science-driven approach has led to multiple publications in top-tier peer-reviewed journals, including the Journal of the American Chemical Society. In his upcoming talk, Dr. Lin will explore the challenges and solutions related to the in vivo stability of novel large molecule conjugates, including antibody-oligonucleotide and Fab conjugates. He will present a multi-pronged approach using LC-MS and capillary electrophoresis-based methods to characterize and quantify biotransformation liabilities. This comprehensive analysis will address the translatability of in vitro findings to in vivo conditions, providing critical insights into linker deconjugation, clipping, and amino acid level modifications. Why is this important? Understanding the in vivo stability of large molecule conjugates is essential for the development of effective biotherapeutics, especially for targeting "undruggable" conditions. Dr. Lin's research offers valuable strategies to overcome these challenges, ensuring better therapeutic outcomes. 📅 Date: October 7-9, 2024 📍 Location: Bristol Myers Squibb, Cambridge, MA  🔗 For more details and registration, visit the APA 2024 Conference website - https://lnkd.in/ecN6EQr Engage with leading experts, delve into cutting-edge research, and be part of the future of pharmaceutical analysis.  #APA2024 #PharmaceuticalAnalysis #Bioanalysis #Biotherapeutics #DrugDevelopment Ju Liu, Jonathan Josephs, John Williams, Jing Tu, Christopher Kochansky, Hiroshi Sugimoto, Hongying Gao, Lina Luo, Zachary Parsons, Yu Tian, Jeff Lin, Nagendra Chemuturi Ph.D., MBA, Aihua Liu

Discover the benefits of using the expert #bioanalytical services of FyoniBio GmbH for your #biopharmaceutical developments! #FyoniBio #AssayDevelopment #Pharmacokinetics